The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance our understanding of the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease and to increase diagnostic precision in detection of the diseases in their early manifestation.
Olink launches Proseek Multiplex – a new generation of multiplexed protein biomarker immunoassays. Until now, it has been impossible to scale up conventional assays due to increased antibody cross-reactivity when large numbers of assays are run simultaneously. With Proseek Multiplex, 92 proteins can be quantified in just one microliter sample without compromising data quality or performance.
Uppsala, Sweden, February 12, 2013 – Olink Bioscience today announced the appointment of Sigma® Life Science, the innovative biological products and services business unit of Sigma-Aldrich Corporation, as distributor of the Duolink® In Situ product line in nearly all geographies worldwide for the research market.
The Duolink® kit from Olink Bioscience enables researchers to use existing antibodies to detect single molecular events, such as protein interactions in unmodified cells and tissue sections. Duolink is based on in situ PLA™ which has the resolution and sensitivity to visualize post-translational modifications and protein interactions, which are fundamental processes in cell signaling pathways.
Duolink in situ PLA technology animation